CN103732062A - 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 - Google Patents

治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 Download PDF

Info

Publication number
CN103732062A
CN103732062A CN201280036988.6A CN201280036988A CN103732062A CN 103732062 A CN103732062 A CN 103732062A CN 201280036988 A CN201280036988 A CN 201280036988A CN 103732062 A CN103732062 A CN 103732062A
Authority
CN
China
Prior art keywords
subject
fumarate
treatment
years
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036988.6A
Other languages
English (en)
Chinese (zh)
Inventor
凯瑟琳·达森
吉尔摩·奥尼尔
阿尔佛雷德·桑德洛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103732062(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN103732062A publication Critical patent/CN103732062A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280036988.6A 2011-05-26 2012-05-25 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 Pending CN103732062A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US61/490,572 2011-05-26
US201261625624P 2012-04-17 2012-04-17
US61/625,624 2012-04-17
PCT/US2012/039721 WO2012162669A1 (en) 2011-05-26 2012-05-25 Methods of treating multiple sclerosis and preserving and/or increasing myelin content

Publications (1)

Publication Number Publication Date
CN103732062A true CN103732062A (zh) 2014-04-16

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036988.6A Pending CN103732062A (zh) 2011-05-26 2012-05-25 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法

Country Status (19)

Country Link
US (1) US20140163100A1 (enExample)
EP (1) EP2713724A4 (enExample)
JP (1) JP2014515373A (enExample)
KR (1) KR20140036257A (enExample)
CN (1) CN103732062A (enExample)
AU (1) AU2012258558A1 (enExample)
BR (1) BR112013030169A2 (enExample)
CA (1) CA2836480A1 (enExample)
CL (1) CL2013003358A1 (enExample)
CO (1) CO6811862A2 (enExample)
EA (1) EA201391578A1 (enExample)
EC (1) ECSP13013117A (enExample)
IL (1) IL229448A0 (enExample)
MX (1) MX2013013781A (enExample)
PE (1) PE20141316A1 (enExample)
PH (1) PH12013502443A1 (enExample)
SG (1) SG195049A1 (enExample)
WO (1) WO2012162669A1 (enExample)
ZA (1) ZA201308681B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106530A (zh) * 2014-11-17 2017-08-29 比奥根玛公司 治疗多发性硬化的方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE380027T1 (de) 2003-09-09 2007-12-15 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
ES2525497T3 (es) 2004-10-08 2015-10-09 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
RU2554347C2 (ru) 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
NZ618178A (en) 2011-06-08 2016-03-31 Biogen Ma Inc Process for preparing high purity and crystalline dimethyl fumarate
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
DK2970101T4 (da) 2013-03-14 2025-11-17 Alkermes Pharma Ireland Ltd Pro-drugs af fumarater og deres anvendelse i behandling af forskellige sygdomme
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
EP3110793B1 (en) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
JP6564868B2 (ja) * 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
WO2016091996A1 (en) 2014-12-11 2016-06-16 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257426A (zh) * 1997-05-20 2000-06-21 富玛法姆股份公司 富马酸衍生物的应用
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20100048651A1 (en) * 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US20080299196A1 (en) * 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
ES2916604T1 (es) * 2007-02-08 2022-07-04 Biogen Ma Inc Ensayos de detección de nrf2 y métodos y composiciones relacionados
CA2760133A1 (en) * 2009-04-29 2010-11-04 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1257426A (zh) * 1997-05-20 2000-06-21 富玛法姆股份公司 富马酸衍生物的应用
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
US20100048651A1 (en) * 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LUDWIG KAPPOS 等: ""Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study"", 《THE LANCET》, vol. 372, no. 9648, 25 October 2008 (2008-10-25), pages 1463 - 1, XP025584415, DOI: doi:10.1016/S0140-6736(08)61619-0 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106530A (zh) * 2014-11-17 2017-08-29 比奥根玛公司 治疗多发性硬化的方法
US10959972B2 (en) 2014-11-17 2021-03-30 Biogen Ma Inc. Methods of treating multiple sclerosis
US11007166B2 (en) 2014-11-17 2021-05-18 Biogen Ma Inc. Methods of treating multiple sclerosis
US11007167B2 (en) 2014-11-17 2021-05-18 Biogen Ma Inc. Methods of treating multiple sclerosis
US11129806B2 (en) 2014-11-17 2021-09-28 Biogen Ma Inc. Methods of treating multiple sclerosis
US11246850B2 (en) 2014-11-17 2022-02-15 Biogen Ma Inc. Methods of treating multiple sclerosis
CN115531366A (zh) * 2014-11-17 2022-12-30 渤健马萨诸塞州股份有限公司 治疗多发性硬化的方法

Also Published As

Publication number Publication date
ZA201308681B (en) 2017-11-29
PE20141316A1 (es) 2014-10-01
WO2012162669A1 (en) 2012-11-29
SG195049A1 (en) 2013-12-30
CL2013003358A1 (es) 2014-08-01
EP2713724A4 (en) 2015-03-11
KR20140036257A (ko) 2014-03-25
JP2014515373A (ja) 2014-06-30
MX2013013781A (es) 2014-01-08
EP2713724A1 (en) 2014-04-09
US20140163100A1 (en) 2014-06-12
BR112013030169A2 (pt) 2016-08-09
EA201391578A1 (ru) 2014-05-30
ECSP13013117A (es) 2014-06-30
AU2012258558A1 (en) 2013-05-02
CA2836480A1 (en) 2012-11-29
PH12013502443A1 (en) 2019-03-22
CO6811862A2 (es) 2013-12-16
IL229448A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
CN103732062A (zh) 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法
JP5474276B2 (ja) 高脂血症治療剤
EP2139467B1 (en) Neuroprotection in demyelinating diseases
US20140329786A1 (en) Combination treatment of cancer
JP2004518653A (ja) 不安障害を治療する方法
AU2008259864C1 (en) Methods and compositions for administration of Oxybutynin
TW202247844A (zh) 吡咯并嘧啶類化合物的用途
EP4420660A1 (en) Use of edaravone in treatment of autism spectrum disorder
JP4972156B2 (ja) ＶＩ型コラーゲン欠損に起因する先天性筋ジストロフィーまたはミオパシーの予防および／または処置のためのＮ−（ジベンゾ（ｂ，ｆ）オキセピン−１０−イルメチル）Ｎ−メチル−Ｎ−プロプ−２−イニルアミン（オミガピル）の使用法
KR20250005055A (ko) 아스피린 및 기타 nsaid의 고 침투성 전구약물을 이용한 심혈관 질환의 예방 또는 치료
EA010868B1 (ru) Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций
JP2019534336A (ja) 多発性骨軟骨腫（ｍｏ）を処置するための方法
JP2004002362A (ja) くしゃみ抑制組成物
US20140186271A1 (en) Reducing dental caries
CN115364102B (zh) 一种吡咯并嘧啶类化合物的应用
US20060281817A1 (en) Treatment for neurodegenerative diseases
WO2004096276A9 (ja) 糖取り込み能増強剤
TW202011949A (zh) 苯甲酸或其鹽及衍生物用於預防或治療抗ｎ－甲基－ｄ－天冬胺酸受體腦炎之用途
KR102902972B1 (ko) Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
JPS6011422A (ja) 抗筋ジストロフイ−症剤
CN1084622C (zh) 药物
JP6216913B1 (ja) 医薬組成物
EP1377277B1 (en) Pharmaceutical compositions comprising pravastatin for reducing ldl cholesterol levels
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140416